Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology
NCT03092518Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Apr 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) and mitomycin c in gastric adenocarcinoma, sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 53.7 months. Started Jun 2017; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)mitomycin c
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03092518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092518.